Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy.

Res Pract Thromb Haemost 2020 Aug 23;4(6):997-1003. Epub 2020 Jul 23.

Monash Haematology Monash Health Melbourne Vic Australia.

Background: In primary central nervous system lymphoma (PCNSL), venous thromboembolism (VTE) can cause significant morbidity and hinder chemotherapy delivery.

Objectives: To assess VTE incidence, timing and adequacy of inpatient and outpatient VTE prophylaxis in patients with PCNSL receiving chemoimmunotherapy with curative intent.

Patients/methods: We reviewed patients diagnosed with PCNSL between 1997 and 2018 who received methotrexate, procarbazine, and vincristine ± Rituximab. Patient demographics, VTE prophylaxis and incidence, adverse events of anticoagulation, and survival outcomes were collected.

Results: Fifty-one PCNSL patients were included (median 67 years [range, 32-87], 30 males [59%]). Thirteen patients (25%, 95% confidence interval [CI], 14-40) developed VTE at a median of 1.6 months from diagnosis (range, 0-4). Patients with Khorana Risk Score ≥2 were more likely to have VTE than those with a KRS < 2 (60% vs 15%;  = .01). Eighty-five percent had deviations from inpatient VTE prophylaxis guidelines, and outpatient prophylaxis was not routinely administered. Three patients required inferior vena cava filters. Hemorrhagic complications of anticoagulation included an intracranial hemorrhage from therapeutic anticoagulation and three cases of major bleeding from prophylactic anticoagulation. No patients died from VTE or its treatment.

Conclusions: Patients with newly diagnosed PCNSL are at high risk of VTE. Further research is required into optimal VTE prophylaxis in PCNSL.

Download full-text PDF

Source
http://dx.doi.org/10.1002/rth2.12415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443429PMC
August 2020

Publication Analysis

Top Keywords

primary central
8
nervous system
8
vte prophylaxis
8
system lymphoma
8
central nervous
8
venous thromboembolism
8
vte
6
patients
5
demographics vte
4
developed vte
4
received methotrexate
4
vte median
4
methotrexate procarbazine
4
procarbazine vincristine ± rituximab
4
14-40 developed
4
vincristine ± rituximab patient
4
patient demographics
4
2018 received
4
patients diagnosed
4
intentpatients/methods reviewed
4

Altmetric Statistics

Similar Publications